MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature
Open Access
- 19 March 2018
- journal article
- review article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 1-5
Abstract
Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of the central nervous system, including patients previously diagnosed with multiple sclerosis (MS). However, only limited data are available on the relevance of MOG-IgG testing in patients with chronic progressive demyelinating disease. It is unclear if patients with primary progressive MS (PPMS) or secondary progressive MS (SPMS) should routinely be tested for MOG-IgG. To evaluate the frequency of MOG-IgG among patients classified as having PPMS or SPMS based on current diagnostic criteria. For this purpose, we retrospectively tested serum samples of 200 patients with PPMS or SPMS for MOG-IgG using cell-based assays. In addition, we performed a review of the entire English language literature on MOG-IgG published between 2011 and 2017. None of 139 PPMS and 61 SPMS patients tested was positive for MOG-IgG. Based on a review of the literature, we identified 35 further MOG-IgG tests in patients with PPMS and 55 in patients with SPMS; the only reportedly positive sample was positive just at threshold level and was tested in a non-IgG-specific assay. In total, a single borderline positive result was observed among 290 tests. Our data suggest that MOG-IgG is absent or extremely rare among patients with PPMS or SPMS. Routine screening of patients with typical PPMS/SPMS for MOG-IgG seems not to be justified.Keywords
Funding Information
- Dietmar Hopp Foundation
- Merck Serono
- German Federal Ministry of Education and Research
- Deutsche Forschungsgemeinschaft
- Austrian Federal Ministry of Science and Economy
- Austrian Research Promotion Agency
- Deutsche Forschungsgemeinschaft
- Universität Heidelberg
- Baden-Württemberg Ministry of Science, Research and the Arts
This publication has 18 references indexed in Scilit:
- Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG DiseaseJAMA Neurology, 2018
- Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?Current Opinion in Neurology, 2017
- Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosisBrain, 2017
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patientsJournal of Neuroinflammation, 2016
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcomeJournal of Neuroinflammation, 2016
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeJournal of Neuroinflammation, 2016
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and originJournal of Neuroinflammation, 2016
- Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?Neurology Neuroimmunology & Neuroinflammation, 2015
- New Multiple Sclerosis Phenotypic ClassificationEuropean Neurology, 2014
- Aquaporin‐4 Antibodies (NMO‐IgG) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the LiteratureBrain Pathology, 2013